Cochrane · systematic review · CD006910
Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer
Newhouse, R, Nelissen, E, El-Shakankery, KH, et al. · Cochrane Database of Systematic Reviews · 2023 · Cochrane Library
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
21
current version
GRADE rated
19
No studies
2
Included studies
NR
No studies 2 · 9.5%Ungraded 0 · 0%Very low 7 · 33.3%Low 3 · 14.3%Moderate 9 · 42.9%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Current version onlySummary of findings 1: PLD with chemotherapy compared to alternative combination chemotherapy in recurrent platinum‐sensitive EOC
Population: adult women with recurrent platinum‐sensitive EOC
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Overall survival (OS) Summary of findings 1: PLD with chemotherapy vs alternative combination chemotherapy | HR 0.93 [0.83, 1.04] | 5 studies · 2006 participants | Moderate Downgraded: risk of bias, imprecision, inconsistency |
Progression‐free survival (PFS) Summary of findings 1: PLD with chemotherapy vs alternative combination chemotherapy | HR 0.81 [0.74, 0.89] | 5 studies · 2006 participants | Moderate Downgraded: risk of bias, imprecision, inconsistency |
Quality of life (QoL) Summary of findings 1: PLD with chemotherapy vs alternative combination chemotherapy | no estimate extracted | 1 study · 608 participants | Low Downgraded: risk of bias, imprecision, inconsistency |
Overall severe adverse events (grade ≥ 3) Summary of findings 1: PLD with chemotherapy vs alternative combination chemotherapy | RR 1.11 [0.95, 1.3] | 2 studies · 834 participants | Moderate Downgraded: risk of bias, imprecision, inconsistency |
Anaemia (grade ≥ 3) Summary of findings 1: PLD with chemotherapy vs alternative combination chemotherapy | RR 1.37 [1.02, 1.85] | 5 studies · 1961 participants | Moderate Downgraded: risk of bias, imprecision, inconsistency |
Hand‐foot syndrome (grade ≥ 3) Summary of findings 1: PLD with chemotherapy vs alternative combination chemotherapy | RR 4.01 [1, 16.01] | 2 studies · 1028 participants | Very low Downgraded: risk of bias, imprecision, inconsistency |
Neurological (grade ≥ 3) Summary of findings 1: PLD with chemotherapy vs alternative combination chemotherapy | RR 0.38 [0.2, 0.74] | 4 studies · 1900 participants | Very low Downgraded: risk of bias, imprecision, inconsistency |
Summary of findings 2: PLD alone compared to other conventional chemotherapy in recurrent platinum‐resistant EOC
Population: adult women with recurrent platinum‐resistant EOC
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Overall survival (OS) Summary of findings 2: PLD alone vs other conventional chemotherapy | HR 0.96 [0.77, 1.19] | 6 studies · 1995 participants | Moderate Downgraded: risk of bias, imprecision, inconsistency, indirectness |
Progression‐free survival (PFS) Summary of findings 2: PLD alone vs other conventional chemotherapy | HR 0.94 [0.85, 1.04] | 4 studies · 1803 participants | Very low Downgraded: risk of bias, imprecision, inconsistency, indirectness |
Quality of life Summary of findings 2: PLD alone vs other conventional chemotherapy | no estimate extracted | NR | No studies |
Overall severe adverse events (grade > 3) Summary of findings 2: PLD alone vs other conventional chemotherapy | no estimate extracted | 2 studies · 964 participants | Very low Downgraded: risk of bias, imprecision, inconsistency, indirectness |
Anaemia (grade ≥ 3) Summary of findings 2: PLD alone vs other conventional chemotherapy | no estimate extracted | 5 studies · 1968 participants | Very low Downgraded: risk of bias, imprecision, inconsistency, indirectness |
Hand‐foot syndrome (grade ≥ 3) Summary of findings 2: PLD alone vs other conventional chemotherapy | no estimate extracted | 6 studies · 2184 participants | Very low Downgraded: risk of bias, imprecision, inconsistency, indirectness |
Neurological (grade ≥ 3) Summary of findings 2: PLD alone vs other conventional chemotherapy | no estimate extracted | 3 studies · 1222 participants | Very low Downgraded: risk of bias, imprecision, inconsistency, indirectness |
Summary of findings 3: PLD with chemotherapy compared to PLD alone in recurrent platinum‐resistant epithelial ovarian cancer
Population: adult women with recurrent platinum‐resistant epithelial ovarian cancer
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Overall survival (OS) Summary of findings 3: PLD with chemotherapy vs PLD alone | HR 0.92 [0.7, 1.21] | 1 study · 242 participants | Moderate Downgraded: risk of bias, imprecision |
Progression‐free survival (PFS) Summary of findings 3: PLD with chemotherapy vs PLD alone | HR 0.94 [0.73, 1.22] | 2 studies · 353 participants | Low Downgraded: risk of bias, imprecision |
Quality of life Summary of findings 3: PLD with chemotherapy vs PLD alone | no estimate extracted | NR | No studies |
Overall severe adverse events (grade ≥ 3) Summary of findings 3: PLD with chemotherapy vs PLD alone | RR 2.48 [1.98, 3.09] | 1 study · 663 participants | Moderate Downgraded: risk of bias, imprecision |
Anaemia (grade ≥ 3) Summary of findings 3: PLD with chemotherapy vs PLD alone | RR 2.38 [1.46, 3.87] | 2 studies · 785 participants | Moderate Downgraded: risk of bias, imprecision |
Hand‐foot syndrome (grade ≥ 3) Summary of findings 3: PLD with chemotherapy vs PLD alone | RR 0.24 [0.14, 0.4] | 2 studies · 785 participants | Moderate Downgraded: risk of bias, imprecision |
Neurological (grade ≥ 3) Summary of findings 3: PLD with chemotherapy vs PLD alone | RR 1.4 [0.85, 2.31] | 1 study · 663 participants | Low Downgraded: risk of bias, imprecision |
Comparison
Population: women with platinum‐sensitive relapsed ovarian cancer
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Progression‐free survival | HR 0.85 [0.74, 0.97] | 2 studies · 1164 participants | High |
Overall survival | HR 1.01 [0.88, 1.17] | 2 studies · 1164 participants | Moderate |
SAE ‐ Hand‐foot syndrome (grade 3) | RR 4.3 [0.92, 20.15] | 2 studies · 1140 participants | Moderate |
SAE ‐ Hair loss (grade 2)² | RR 0.09 [0.06, 0.15] | 2 studies · 1140 participants | High |
Discontinuation due to toxicity | RR 0.38 [0.26, 0.57] | 2 studies · 1150 participants | High |
Comparison
Population: women with platinum‐resistant (PR) or platinum‐sensitive (PS) relapsed ovarian cancer
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
PFS: PR and PS disease TBD/PLD versusPLD | HR 0.79 [0.65, 0.96] | 1 study · 672 participants | Moderate |
PFS: PPS disease only PLD/TBD versusPLD | HR 0.65 [0.45, 0.93] | 1 study · 208 participants | Moderate |
OS: PR and PS disease TBD/PLD versusPLD | HR 0.86 [0.72, 1.02] | 1 study · 672 participants | Moderate |
PFS: PR disease only EC145/PLD versusPLD | HR 0.63 [0.41, 0.97] | 1 study · 149 participants | Low |
OS: PR disease only EC145/PLD versusPLD | HR 1.01 [0.68, 1.5] | 1 study · 149 participants | Very low |
Comparison
Population: women with relapsed ovarian cancer
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
SAE: HFS (grade 3) subgrouped by PLD dose | RR 4.63 [1.32, 16.19] | 4 studies · 1344 participants | High |
SAE: Stomatitis (grade 3 to 4) subgrouped by PLD dose | RR 2.22 [0.87, 5.67] | 4 studies · 1283 participants | High |